Versant debut earnings report shows continued pay TV pressure, digital growth

Versant debut earnings report shows continued pay TV pressure, digital growth


Versant debut earnings report shows continued pay TV pressure, digital growth

Versant Media Group, the newly minted spinout of TV networks and digital assets from Comcast, released its first earnings report on Tuesday. 

The company reported full-year revenue of roughly $6.69 billion for 2025, down 5% from the prior year. Versant is reporting a breakdown of its earnings from its final year under the ownership of Comcast’s NBCUniversal. 

Versant’s linear distribution revenue was down 5.4% to $4.1 billion, and advertising revenue declined almost 9% to $1.58 billion. 

Net income attributable to Versant was $930 million, and the company reported $2.18 billion in standalone adjusted earnings before interest, taxes, depreciation and amortization. 

Shares of Versant gained 5% in premarket trading Tuesday.

For the quarter ended Dec. 31, Versant’s total revenue was down nearly 7% to $1.61 billion, according to a Securities and Exchange filing on Tuesday. Specifically, linear distribution revenue was down almost 6% to $997 million and ad revenue declined 9% to $370 million, while platforms revenue was roughly flat at $202 million.

Standalone adjusted EBITDA for the quarter was $521 million, down 19% from the same period last year.

The company’s board also declared a $0.375 per share quarterly dividend, which represents an annualized dividend of $1.50 per share, and authorized a $1 billion share repurchase program. Due to its low debt load and high-margin business, Versant executives have said they plan to return value to shareholders. 

Versant marked its first day as a standalone company earlier this year, and started trading on the Nasdaq in early January. However, Versant’s management had been working throughout 2025 on the separation of the assets from Comcast. 

The company is made up of a portfolio of pay TV networks including CNBC, MS Now, USA Network, Golf Channel, Syfy, E! And Oxygen, as well as digital properties such as Fandango, Rotten Tomatoes, GolfNow and Sports Engine. 

The traditional TV business, while still profitable, has seen continued losses over the years  across all media companies as viewers exit the bundle for streaming alternatives. 

More than 80% of Versant’s revenue leans on the pay TV business, but its executives have told Wall Street that 2026 will be a year of transition for its business model. The company aims to eventually reach 50% of its revenue from digital, platform, subscription, ad-supported and transactional businesses. 

On Tuesday, Versant reported that its non-pay TV revenue reached 19% of total revenue in 2025, with roughly $826 million in platforms revenue. Versant’s platform business was the only revenue segment to grow revenue year over year. 

It considers its growth drivers in that unit to include MS Now’s upcoming direct-to-consumer product, CNBC Pro and a new retail investor product for the brand, and the launch of the ad-supported Fandango at Home service in 2026. 

Disclosure: Versant is the parent company of CNBC.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More